Patient Reported Outcome study of Dapagliflozin on glycemic control and treatment satisfaction in overweight patients with type 2 diabetes mellitus
Phase of Trial: Phase III
Latest Information Update: 28 Nov 2017
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Overweight; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms PRO
- 24 Nov 2017 Status changed from active, no longer recruiting to completed.
- 30 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 28 Jan 2015 New trial record